The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 6, 2000, Pages 495-501

  Fumagalli, Luca ^a,b   Zucchetti, Massimo ^b   Parisi, Idria ^b   Viganò, Maria Grazia ^a   Zecca, Bruno ^a   Careddu, Anna ^a   D'Incalci, Maurizio ^c   Lazzarin, Adriano ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c NONE

Author keywords

Antiretroviral therapy; Kaposi's sarcoma; Liposomal daunorubicin; Pharmacokinetics; Protease inhibitors

Indexed keywords

DAUNORUBICIN; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0034075437     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051025     Document Type: Article

References (49)

1. 1. Aboulafia DM (1998) Regression of acquired immunodeficiency syndrome-related pulmonary Kaposi's sarcoma after highly active antiretroviral therapy. Mayo Clin Proc 73: 439
2. 2. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, Leibowitch J (1997) Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277: 112
3. 3. Blum L, Pellet C, Agbalika F, Blanchard G, Morel P, Calvo F, Lebbe C (1997) Complete remission of AIDS-related Kaposi's sarcoma associated with undetectable human herpesvirus-8 sequences during anti-HIV protease therapy. AIDS 11: 1653
4. 4. Broggini M, Italia C, Colombo T, Marmonti L, Donelli MG (1984) Activity and distribution of iv and oral 4-demethoxyd-aunorubicin in murine experimental tumors. Cancer Treat Rep 68: 739
5. 5. Cadranel JL, Kammoun S, Chevret S, Parrot A, Denis M, Winter C, Carette MF, Rozenbaum W, Akoun GM, Mayaud CM (1994) Results of chemotherapy in 30 AIDS patients with symptomatic pulmonary Kaposi's sarcoma. Thorax 49: 958
6. 6. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA (1998) Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 280: 78
7. 7. Conant MA, Opp KM, Poretz D, Mills RG (1997) Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonavir. AIDS 11: 1300
8. 8. Ebrahim SH, Peterman TA, Zaidi AA, Hamers FF (1997) Geography of AIDS-associated Kaposi's sarcoma in Europe. AIDS 11: 1739
9. 9. Egorin MJ (1993) Therapeutic drug monitoring and dose optimization in oncology. In: Workman P (ed) New approaches in cancer pharmacology: drug design and development. Springer-Verlag, Berlin, p 75
10. 10. Ensoli B, Gendelman R, Markham P, Fiorelli V, Colombini S, Raffeld M, Cafaro A, Chang HK, Brady JN, Gallo RC (1994) Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 371: 674
11. 11. Flexner C (1998) HIV-protease inhibitors. N Engl J Med 338: 1281
12. 12. Forrest DM, Seminari E, Hogg RS, Yip B, Raboud J, Lawson L, Phillips P, Schechter MT, O'Shaughnessy MV, Montaner JS (1998) The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. Clin Infect Dis 27: 1379
13. 13. Gabizon A, Dagan A, Goren D, Barenholz Y, Fuks Z (1982) Liposomes as in vivo carriers of Adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res 42: 4734
14. 14. Gill PS, Akil B, Colletti P, Rarick M, Loureiro C, Bernstein-Singer M, Krailo M, Levine AM (1989) Pulmonary Kaposi's sarcoma: clinical findings and results of therapy. Am J Med 87: 57
15. 15. Gill PS, Espina BM, Muggia F, Cabriales S, Tulpule A, Esplin JA, Liebman HA, Forssen E, Ross ME, Levine AM (1995) Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 13: 996
16. 16. Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, Roenn JH von, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross MEB (1996) Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 14: 2353
17. 17. Goedert JJ, Cote TR, Virgo P, Scoppa SM, Kingma DW, Gail MH, Jaffe ES, Biggar RJ (1998) Spectrum of AIDS-associated malignant disorders. Lancet 351: 1833
18. 18. Grunaug M, Bogner JR, Loch O, Goebel FD (1998) Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. Eur J Med Res 3: 13
19. 19. Guaglianone P, Chan K, DelaFlor-Weiss E, Hanisch R, Jeffers S, Sharma D, Muggia F (1994) Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest New Drugs 12: 103
20. 20. Harrington W Jr, Sieczkowski L, Sosa C, Chan-a-Sue S, Cai JP, Cabral L, Wood C (1997) Activation of HHV-8 by HIV-1 tat. Lancet 349: 774
21. 21. Jung C, Bogner JR, Goebel F (1998) Resolution of severe Kaposi's sarcoma after initiation of antiretroviral triple therapy. Eur J Med Res 3: 439
22. 22. Krigel RL, Laubenstein LJ, Muggia FM (1983) Kaposi's sarcoma: a new staging classification. Cancer Treat Rep 67: 531
23. 23. Krown SE, Metroka C, Wernz JC (1989) Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 7: 1201
24. 24. Landriani GS, Guardabasso V, Rocchetti M (1983) NL-FIT: a microcomputer program for non-linear fitting. Comput Programs Biomed 16: 35
25. 25. Lebbe C, Blum L, Pellet C, Blanchard G, Verola O, Morel P, Danne O, Calvo F (1998) Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 12: F45
26. 26. Little RF, Pearson D, Elwood P, Franchini G, Yarchoan R, Wilson WH (1999) Evidence of immune reconstitution and HIV control following EPOCH chemotherapy (CT) for HIV-related lymphomas (HIV-NHL). Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, Ill. (http:// www.retroconference.org/99/abstracts/206.htm)
27. 27. Martinelli C, Zazzi M, Ambu S, Bartolozzi D, Corsi P, Leoncini F (1998) Complete regression of AIDS-related Kaposi's sarcoma-associated human herpesvirus-8 during therapy with indinavir. AIDS 12: 1717
28. 28. Masood R, Husain SR, Rahman A, Gill P (1993) Potentiation of cytotoxicity of Kaposi's sarcoma related to immunodeficiency syndrome (AIDS) by liposome-encapsulated doxorubicin. AIDS Res Hum Retroviruses 9: 741
29. 29. Mastroianni A, Coronado O, Cancellieri C, Manfredi R, Pignatari S, Chiodo F (1998) Pulmonary Kaposi's sarcoma in AIDS patients treated with combined chemotherapy and recombinant human granulocyte colony-stimulating factor. J Chemother 10: 405
30. 30. McGarvey ME, Tulpule A, Cai J, Zheng T, Masood R, Espina B, Arora N, Smith DL, Gill PS (1998) Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma. Curr Opin Oncol 10: 413
31. 31. Michaels SH, Clark R, Kissinger P (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 339: 405
32. 32. Miles AS, Mitsuyasu RI, Aboulafia DM (1997) AIDS-related malignancies. In: DeVita VT Jr, Hellman S, Rosenberg SA (ed) Cancer: principles and practice of oncology. Lippincott-Raven, Philadelphia, p 2445
33. 33. Miller AA, Stewart CF, Tolley EA (1990) Clinical pharmaco-dynamics of continuous-infusion etoposide. Cancer Chemother Pharmacol 25: 361
34. 34. Moltke LL von, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, Daily JP, Harmatz JS, Shader RI (1998) Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 38: 106
35. 35. Murphy M, Armstrong D, Sepkowitz KA, Ahkami RN, Myskowski PL (1997) Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor. AIDS 11: 261
36. 36. No authors named (1998) Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and the Henry J. Kaiser Family Foundation. Ann Intern Med 128: 1079
37. 37. No authors named (1998) Report of the NIH Panel To Define Principles of Therapy of HIV Infection. Ann Intern Med 128: 1057
38. 38. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH (1998) Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16: 2445
39. 39. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853
40. 40. Parra R, Leal M, Delgado J, Macias J, Rubio A, Gomez F, Soriano V, Sanchez-Quijano A, Pineda JA, Lissen E (1998) Regression of invasive AIDS-related Kaposi's sarcoma following antiretroviral therapy. Clin Infect Dis 26: 218
41. 41. Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H (1996) Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 23: 685
42. 42. Sahai J (1996) Risks and synergies from drug interactions. AIDS 10: S21
43. 43. Sparano JA, Wiernik PH, Hu X, Sarta C, Henry DH, Ratech H (1998) Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma. Med Oncol 15: 50
44. 44. Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios A, Aboulafia D, Galleshaw J, Dezube BJ (1998) Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 16: 683
45. 45. Tan B, Ratner L (1997) The use of new antiretroviral therapy in combination with chemotherapy. Curr Opin Oncol 9: 455
46. 46. Tulpule A, Yung RC, Wernz J, Espina BM, Myers A, Scadden DT, Cabriales S, Ilaw M, Boswell W, Gill PS (1998) Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma. J Clin Oncol 16: 3369
47. 47. Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP (1999) Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 179: 717
48. 48. White RM (1997) Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma. AIDS 11: 1412
49. 49. Wit FW, Sol CJ, Renwick N, Roos MT, Pals ST, Leeuwen R van, Goudsmit J, Reiss P (1998) Regression of AIDS-related Kaposi's sarcoma associated with clearance of human herpes-virus-8 from peripheral blood mononuclear cells following initiation of antiretroviral therapy. AIDS 12: 218